Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting.